Curemark products

The U.S. Centers for Disease Control and Prevention estimate that 1 in 68 children in the United States have been diagnosed with Autism. There is currently no approved drug on the market that treats the core symptoms of Autism. At Curemark, we are working to change that. Curemark’s lead drug candidate, CM-AT, has received “Fast Track” designation from the U.S. Food and Drug Administration (FDA). FDA has also granted Curemark a rolling review of its New Drug Application for CM-AT.

More than 5 million children in the U.S., aged 4-17 years old, have been diagnosed with Attention-Deficit Hyperactivity Disorder (ADHD). The condition is characterized by inattention, hyperactivity and impulsivity. Current prescription medications and psychosocial therapies focus on ameliorating primary symptoms. No currently approved drug treats the underlying cause of ADHD, and there is no known cure. Our pipeline includes a Phase III-ready drug product for ADHD. Preliminary studies with patients diagnosed with ADHD and taking prescribed ADHD medication indicate that these children could benefit from the administration of our product, CM-4612.

Patient-centered drug discovery is at the core of what we do at Curemark. We approach neurological disorders from a translational and innovative perspective.